ANB101 — Initial data
2026
ANB101 (BDCA2 modulator): on track for Phase 1 results in 2026;Source filing
ANAB biotech catalysts & pipeline
ANAPTYSBIO INC · Data as of 2026-09-08
Upcoming catalysts
Jemperli (dostarlimab) — Topline data
H2 2026
Top-line data H2 20265Source filing
ANB033 — Topline data
Q4 2026
Top-line Phase 1b data for both cohorts anticipated in Q4 2026Source filing
Jemperli (dostarlimab) — Topline data
Q4 2026
Top-line data expected in Q4 2026Source filing
imsidolimab — PDUFA
Dec 12
FDA target action date (PDUFA) of Dec. 12, 2026 for imsidolimab in generalized pustular psoriasis (GPP)Source filing
Jemperli (dostarlimab) — Topline data
2028
Data expected in 2028Source filing